Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 long-term extension in narcolepsy type 1 and type 2
NL-OMON53942Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of oveporexton in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) (6 arms), sponsored by Takeda. Primary endpoint: Occurrence of at least 1 treatment-emergent adverse event. Started Jun 2023; status: recruiting.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NL-OMON53942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53942.